TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03412123

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: group lifestyle-integrated functional exercise
Description: Manualized teaching of balance and strength principles and integration of exercises and physical activity into daily routine during 7 sessions in a group of 8 to 10 participants with 2 trainers. The pilot intervention group will undergo the same strength and balance exercises and learn about the same physical activity enhancement strategies as described in the LiFE programme by Clemson et al. (BMJ 2012;345:e4547). However, instead of 7 home visits, gLiFE participants will attend seven group sessions (1 session/week). In these, LiFE contents are adapted to the group setting and enhanced by health psychological and behaviour change strategies fitting to the social structure and modalities of a group.
Study: NCT03523949

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PNE
Description: The PNE will be delivered by a physiotherapist in a single, group-based session.
Study: NCT03352128

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine
Description: Participants will have to supplement themselves with creatine for 7 days (20g/day).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium lactate
Description: Participants will have to supplement themselves with calcium lactate for 7 days (elemental calcium: 0.780g/day).
Study: NCT04572893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danicamtiv
Description: Myosin activator
Study: NCT02666690

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CEUS (Contrast-enhanced ultrasound)
Description: Each patient will be performed 2 contrast echocardiography (a pre-prandial - a post-prandial) before the antiangiogenic treatment, at D15 and D30.
Study: NCT01544478

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V501
Description: HPV types 6, 11, 16, and 18 vaccine 0.5 mL by intramuscular injection at Day 1, Month 2, and Month 6
Study: NCT02019745

Intervention type: BIOLOGICAL
Intervention: LAIV
Description: Standard dose of LAIV administered by a licensed health care providers.
Study: NCT00250497

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New Moves
Description: The New Moves intervention is an all girls physical education class that provides a supportive environment for girls. Girls participate in noncompetitive physical activities. They also receive lessons on nutrition and social support. After the class is over, girls continue to receive intervention messages through weekly lunch meetings. Girls meet individually with a personal coach.
Study: NCT01082003

Intervention type: DRUG
Group type: OTHER
Intervention: Trental
Description: Trental (pentoxifylline) 400 milligrams three times a day in combination with vitamin E, 400 international units orally twice daily for six months.

Intervention type: DRUG
Group type: OTHER
Intervention: Trental
Description: Trental (pentoxifylline) 400 milligrams three times a day in combination with vitamin E, 400 international units orally twice daily for six months.
Study: NCT03429764

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CISS
Description: continuous independent sling sutures will be placed with minimum two intact contact points at the surgical site

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VIMS
Description: internal mattress suture will be placed with minimum two intact contact points at the surgical site
Study: NCT03891615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib is a type of drug called a PARP inhibitor, which blocks DNA (the genetic material of cells) damage from being repaired or may prevent damage from occurring in the first place. In cancer treatment, inhibiting PARP may help kill cancer cells through deadly DNA damage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib blocks mutated EGFR, which may cause tumor regression (when the tumor starts to shrink) and prevent the spread of the cancer.
Study: NCT04758741

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Investigating the impact of Acceptance and Commitment Therapy on Resiliency in women affected by domestic violence

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: placebo
Description: This rct has one arm and health education is done only for the purpose of blinding the study so that the participant does not know which of the control or intervention groups it is in and has no comparative aspect and has nothing to do with resilience
Study: NCT00300534

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Abbott Laboratories Determine test for syphilis

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Investigational syphilis immunochromatographic strip test
Study: NCT01591811

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Arm 1 Daily Boost of Radiation Therapy
Description: Arm 1 Daily boost. IMRT at 2.7Gy x15 fractions. Total dose 40.50Gy. Daily Boost 0.5Gy to tumor bed x 15 fractions. Tumor Bed Total=48Gy
Study: NCT03486548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine and dexamethasone
Description: adductor canal block with 0.33% bupivacaine 15 ml with ultrasound guided popliteal sciatic block with 0.125% bupivacaine 20 ml and dexamethasone 5 mg
Study: NCT01591811

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Arm 2 Weekly Boost of Radiation Therapy
Description: Arm2: IMRT at 2.7Gy x 15 fractions. Total Dose=40.50 Gy. Weekly Boost 2Gy (on Friday). Tumor Bed Total 46.50Gy
Study: NCT04327050

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic anchored guided endoscopic submucosal dissection
Description: Using magnetic anchoring technology, the magnetic pulling unit is anchored to the abdominal wall, and micro surgical tweezers are used. The tumor tissue is pulled indirectly, so that the mucosa is lifted up, which is beneficial to the peeling of the submucosa.
Study: NCT01759355

Intervention type: PROCEDURE
Intervention: FDG PET/MR
Description: Participants will undergo a FDG, gadolinium enhanced PET/MR scan.

Intervention type: PROCEDURE
Intervention: FDG PET/MR
Description: Participants will undergo a FDG, gadolinium enhanced PET/MR scan.
Study: NCT00882830

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EMS
Description: EMS sessions on both lower extremities (quadriceps and peroneus longus) simultaneously.
Study: NCT01496404

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrocautery
Description: Electrocautery using cutting mode of epidermis and dermis of skin.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scalpel
Description: Incising skin (epidermis and dermis) with scalpel.
Study: NCT02378493

Intervention type: BIOLOGICAL
Intervention: Antibiofilmogramme
Description: An Antibiofilmogramme (BioFilm Control) evaluates the capacity of a series of antibiotics to inhibit the growth of bacterial biofilms for a given bacterial isolate.

Intervention type: BIOLOGICAL
Intervention: Antibiofilmogramme
Description: An Antibiofilmogramme (BioFilm Control) evaluates the capacity of a series of antibiotics to inhibit the growth of bacterial biofilms for a given bacterial isolate.
Study: NCT04500067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIG
Description: Patients in the study group receive the drug Bioven, 10% solution for infusions produced by LLC Biopharma Plasma 0,8-1,0 g/kg once a day for 2 days (total course dose - 1.6-2.0 g/kg) as well as base treatment recommended by the protocol of COVID-19 coronavirus infection treatment depending on the severity of their condition according to the prescription sheet.
Study: NCT03486548

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: bupivacaine and lidocaine
Description: adductor canal block with 0.33% bupivacaine 15 ml with ultrasound at popliteal sciatic area and subcutaneous infiltration popliteal area with 2% lidocaine 1 ml

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Ultrasound
Description: ultrasound

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: ultrasound
Study: NCT02845505

Intervention type: OTHER
Intervention: Intravascular Ultrasound, coronary computed tomography angiography
Study: NCT03416530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC201
Description: ONC201 is a orally active, small molecule DRD2 antagonist that kills cancer cells but not normal cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC201
Description: ONC201 is a orally active, small molecule DRD2 antagonist that kills cancer cells but not normal cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC201
Description: ONC201 is a orally active, small molecule DRD2 antagonist that kills cancer cells but not normal cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC201
Description: ONC201 is a orally active, small molecule DRD2 antagonist that kills cancer cells but not normal cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC201
Description: ONC201 is a orally active, small molecule DRD2 antagonist that kills cancer cells but not normal cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC201
Description: ONC201 is a orally active, small molecule DRD2 antagonist that kills cancer cells but not normal cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC201
Description: ONC201 is a orally active, small molecule DRD2 antagonist that kills cancer cells but not normal cells.
Study: NCT04170816

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: DN and KT therapy will be applied 3 sessions in 1-week intervals

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: DN and KT therapy will be applied 3 sessions in 1-week intervals
Study: NCT04730284

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health supplements
Description: tailor-made Synbiotics, 4g per day for 28 days
Study: NCT04012983

Intervention type: DIAGNOSTIC_TEST
Intervention: gingival crevicular fluid level
Description: gingival crevicular fluid collection

Intervention type: DIAGNOSTIC_TEST
Intervention: gingival crevicular fluid level
Description: gingival crevicular fluid collection

Intervention type: DIAGNOSTIC_TEST
Intervention: gingival crevicular fluid level
Description: gingival crevicular fluid collection
Study: NCT04362982

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADHD360 platform: An intervention intergrating a serious game along with a mobile application for daily behavioral monitoring.
Description: Clinical trials will include two parts. The first part includes three visits. In the first visit, children and their parents will come to the Laboratory of Medical Physics to be informed regarding the experimental procedures, sign the consent form and familiarize with the scientific staff involved in the project as well as the lab enviroment. In the second visit, children will undergo an neuropsychological assessment delivered by an experienced pscychologist. Afterwards, they will interact with the ADHD360 platfrom for 30-45 minutes. In the third visit, participants will interact with the ADHD360 platfrom for 30-45 minutes. In the second part, participants will use the ADHD360 platfrom two or three times per week for about 30-45 minutes. At the end of the second part, participants will undergo a neuropsychological evalutation following the same procedures as the first one.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ADHD360 platform: An intervention intergrating a serious game along with a mobile application for daily behavioral monitoring.
Description: Clinical trials will include two parts. The first part includes three visits. In the first visit, children and their parents will come to the Laboratory of Medical Physics to be informed regarding the experimental procedures, sign the consent form and familiarize with the scientific staff involved in the project as well as the lab enviroment. In the second visit, children will undergo an neuropsychological assessment delivered by an experienced pscychologist. Afterwards, they will interact with the ADHD360 platfrom for 30-45 minutes. In the third visit, participants will interact with the ADHD360 platfrom for 30-45 minutes. In the second part, participants will use the ADHD360 platfrom two or three times per week for about 30-45 minutes. At the end of the second part, participants will undergo a neuropsychological evalutation following the same procedures as the first one.
Study: NCT02092493

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ScopeGuide
Description: These patient will have their procedure undertake with the use of ScopeGuide, which provides a 3d configuration of the colonoscope in the patient
Study: NCT02568800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prolonged Cefepime Infusion
Description: Cefepime infusion should last at least 4 hours with the aide of an infusion bomb
Study: NCT04334772

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Muscle belly Microelectrolysis
Description: three applications of direct current at 600 µA interrupted by intervals of 30 seconds between application at the level of the muscular belly of the shortened hamstrings.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tendon Microelectrolysis
Description: three applications of direct current at 600 µA interrupted by intervals of 30 seconds between application in the tendon of the shortened hamstrings.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching exercises
Description: 5 sets of passive static hamstring stretches using the straight leg extension (SLR) test for a time of 30 seconds and interval of 30 seconds for each

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching exercises
Description: 5 sets of passive static hamstring stretches using the straight leg extension (SLR) test for a time of 30 seconds and interval of 30 seconds for each
Study: NCT02568800

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual Cefepime Infusion
Description: Cefepime infusion occurs directly without the aide of an infusion bomb, lasting roughly thirty minutes
Study: NCT03166735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1467335
Description: once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1467335
Description: once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1467335
Description: once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1467335
Description: once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily
Study: NCT00791960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dimenhydrinate
Description: single dose, 25mg, IV, diluted in 9.5mL normal saline.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose, 10 mL normal saline, IV
Study: NCT03717818

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Good Psychiatric Management - Brief
Description: specific interventions as defined by Gunderson and Links (2014)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: treatment as usual
Description: non-specific intervention
Study: NCT03797014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: Fixed dose combination B/F/TAF (50 mg/ 200 mg/ 25 mg/ tablet) administered orally once daily without regards to food.
Study: NCT01292746

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia MLS
Description: The Erchonia MLS administers 4 diodes of 10 milliwatts (mW) 635 nanometers (nm) red light to the scalp area for 18 minutes, 2 times each week for 12 consecutive weeks for a total of 24 treatments.
Study: NCT04334772

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching exercises
Description: 5 sets of passive static hamstring stretches using the straight leg extension (SLR) test for a time of 30 seconds and interval of 30 seconds for each
Study: NCT04450641

Intervention type: OTHER
Group type: OTHER
Intervention: GuessWhat Mobile Application
Description: The GuessWhat app is a charades style game and app that engages parent and child in fluid social interaction where the parent must guess what the child is acting out based on the prompt shown on the phone screen. Participants will use their own personal phone to download the study app. Parent and child will be encouraged to play using the emojis and emotion game mode at least 3 individual game sessions per week. Parents are asked to play GuessWhat with their child 3-4 times per week for 4 weeks.
Study: NCT00918138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 5 mg, once daily, 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin XR
Description: Tablets, Oral, 1500 mg, once daily, 4 weeks
Study: NCT04450641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GuessWhat Mobile Application
Description: The GuessWhat app is a charades style game and app that engages parent and child in fluid social interaction where the parent must guess what the child is acting out based on the prompt shown on the phone screen. Participants will use their own personal phone to download the study app. Parent and child will be encouraged to play using the emojis and emotion game mode at least 3 individual game sessions per week. Parents are asked to play GuessWhat with their child 3-4 times per week for 4 weeks.
Study: NCT04499638

Intervention type: DEVICE
Intervention: Peripheral vascular catheters
Description: Carry time of common peripheral vascular devices in clinical practice and the reason for his withdrawal

Intervention type: DEVICE
Intervention: Peripheral vascular catheters
Description: Carry time of common peripheral vascular devices in clinical practice and the reason for his withdrawal
Study: NCT05221593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: 400 mg tablet in controlled released formula
Study: NCT02842541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBI-031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBI-031
Study: NCT00918138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR
Description: Tablets, Oral, 1500 mg, once daily, 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching Metformin XR
Description: Tablets, Oral, 0 mg, once daily, 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin XR
Description: Tablets, Oral, 500 mg, once daily, 4 weeks
Study: NCT01896661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diuretics
Description: Chlorthalidone plus amiloride 25 and 5 mg daily, taking in the morning

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Channel Blockers
Description: Amlodipine 10 mg daily, taking in the morning
Study: NCT03241589

Intervention type: OTHER
Intervention: Direct to patient facing mobile apps introduction
Description: VA employees and Veterans begin use of OCC's direct to patient facing mobile app.

Intervention type: OTHER
Intervention: Direct to patient facing mobile apps introduction
Description: VA employees and Veterans begin use of OCC's direct to patient facing mobile app.
Study: NCT04189640

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative analgesia management
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure. If the VAS score will be ≥ 4, 0.5 mg/ kg tramadol IV will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative analgesia management
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure. If the VAS score will be ≥ 4, 0.5 mg/ kg tramadol IV will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative analgesia management
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure. If the VAS score will be ≥ 4, 0.5 mg/ kg tramadol IV will be administered.
Study: NCT00918346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafluprost 0.0015%
Description: Eye drops, 0.015 mg/ml, once daily to affected eye(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafluprost 0.0015%
Description: Eye drops, 0.015 mg/ml, once daily to affected eye(s)
Study: NCT01761994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulation with nafamostat mesilate
Description: Initial dose of nafamostat mesilate is 20mg/hr. Dosage is adjusted from 10mg to 30mg/hr according to patients' status. For priming, two vial of nafamostat mesilate was dissolved in 2mL of 5% glucose fluid, and then mixed with 1000mL of normal saline. After carefully removing air bubble from the circuit with the prepared fluid, nafamostat mesilate was dissolved with 15 mL of 5% glucose fluid and loaded in anticoagulation line with starting dose of 20mg/hr.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulation with nafamostat mesilate
Description: Initial dose of nafamostat mesilate is 20mg/hr. Dosage is adjusted from 10mg to 30mg/hr according to patients' status. For priming, two vial of nafamostat mesilate was dissolved in 2mL of 5% glucose fluid, and then mixed with 1000mL of normal saline. After carefully removing air bubble from the circuit with the prepared fluid, nafamostat mesilate was dissolved with 15 mL of 5% glucose fluid and loaded in anticoagulation line with starting dose of 20mg/hr.
Study: NCT03456180

Intervention type: DEVICE
Intervention: Haemoadsorption with Cytosorb cartridge
Description: microcirculatory monitoring in septic shock patients requiring renal replacement therapy for acute renal failure and haemoadsorption with Cytosorb cartridge
Study: NCT00159380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminoguanidine
Description: 500mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: 2ml
Study: NCT01209806

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simethicone
Description: 400 mg simethicone at 6pm night prior to colonoscopy 400 mg simethicone 4 hours before colonoscopy
Study: NCT03049072

Intervention type: RADIATION
Intervention: Protons and Carbon Ions